All In Biotech

Drug Trial Radar · NCT01232556

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN ADMINISTERED IN COMBINATION WITH RITUXIMAB COMPARED TO DEFINED INVESTIGATOR'S CHOICE THERAPY IN SUBJECTS WITH RELAPSED OR REFRACTORY CD22-POSITIVE AGGRESSIVE NON-HODGKIN LYMPHOMA WHO ARE NOT CANDIDATES FOR INTENSIVE HIGH-DOSE CHEMOTHERAPY

Last checked: Nov 20, 2026Latest source record: Jan 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 338 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

338

Actual

Start

Apr 4, 2011

Primary completion

Mar 28, 2014

Study completion Mar 28, 2014

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
UCB Pharma
First posted
Nov 2, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of inotuzumab ozogamicin plus rituximab in relapsed/refractory aggressive Non-Hodgkin lymphoma patients who are not candidates for intensive high-dose chemotherapy. Specifically, the goal is to demonstrate the superiority of this combination compared with an active comparator arm (investigator's choice of rituximab+bendamustine or rituximab+gemcitabine) using the primary endpoint of overall survival.

Conditions

  • Lymphoma, Non-Hodgkin

Interventions

  • Inotuzumab ozogamicinDrug

    1.8 mg/m2 on day 2 every 28 days by IV infusion, 3 to 6 cycles

  • RituximabDrug

    375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles

  • rituximab + gemcitabineDrug

    rituximab 375 mg/m2 on days 1, 8, 15, and 22 of cycle 1, and day 1 of cycles 2 to 6, every 28 days by IV infusion, 3 to 6 cycles; gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days, 3 to 6 cycles

  • rituximab +bendamustineDrug

    rituximab 375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles; bendamustine 120 mg/m2 on days 1 and 2 by IV infusion every 28 days, 3 to 6 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: From randomization up to 5 years after last dose or up to final study visit, whichever occurs first.
  2. Percentage of Participants With a Treatment Emergent Adverse Event (TEAE) (Safety Population)Time frame: Up to 20 weeks after the first dose of study drug

Locations

177 sites in 25 countries. Site status is shown where the registry gives one.

  • Disney Family Cancer Center at Providence St Joseph Medical Center

    Burbank, California

  • Providence St Joseph Medical Center

    Burbank, California

  • Hematology-Oncology Medical Group of Fresno Inc

    Fresno, California

  • Ronald Reagan UCLA Medical Center Drug Information Center Department of Pharmaceutical Services

    Los Angeles, California

  • Clinical Research Unit

    Los Angeles, California

  • Peter Morton Medical Plaza

    Los Angeles, California

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California

  • Sansum Clinic

    Santa Barbara, California

  • UCLA Santa Monica Hematology Oncology

    Santa Monica, California

  • Sansum Clinic

    Solvang, California

  • Howard University Hospital

    Washington D.C., District of Columbia

  • Mount Sinai Comprehensive Cancer Center at Aventura

    Aventura, Florida

  • University Cancer Institute

    Boynton Beach, Florida

  • 21st Century Oncology of Jacksonville, LLC

    Fernandina Beach, Florida

  • Davis Cancer Pavilion and Shands Medical Plaza

    Gainesville, Florida

  • Shands Cancer Hospital at the University of Florida

    Gainesville, Florida

  • UF Health Davis Cancer Pavillion and Shands Med Plaza

    Gainesville, Florida

  • UF Health Shands Cancer Hospital

    Gainesville, Florida

  • Shands Hospital at the University of Florida

    Gainesville, Florida

  • UF Health Shands Hospital

    Gainesville, Florida

  • 21st Century Oncology of Jacksonville, LLC

    Jacksonville, Florida

  • 21st Century Oncology of Jacksonville, LLC

    Jacksonville, Florida

  • Baptist Cancer Institute

    Jacksonville, Florida

  • Baptist Medical Center

    Jacksonville, Florida

  • 21st Century Oncology of Jacksonville, LLC

    Jacksonville, Florida

  • 21st Century Oncology of Jacksonville, Inc.

    Jacksonville, Florida

  • Medical Specialists Of The Palm Beaches

    Lake Worth, Florida

  • Advanced Medical Specialties

    Miami, Florida

  • Mercy Hospital

    Miami, Florida

  • Mercy Research Institute

    Miami, Florida

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida

  • Mount Sinai Medical Center

    Miami Beach, Florida

  • 21st Century Oncology of Jacksonville, LLC

    Orange Park, Florida

  • Georgia Regents Medical Cancer Pharmacy

    Augusta, Georgia

  • Georgia Regents University

    Augusta, Georgia

  • Kootenai Cancer Center

    Coeur d'Alene, Idaho

  • Kootenai Cancer Center

    Post Falls, Idaho

  • Decatur Memorial Hospital (DMH)

    Decatur, Illinois

  • Floyd Memorial Cancer Center of Indiana

    New Albany, Indiana

  • University of Kansas Medical Center

    Kansas City, Kansas

Showing 40 of 177 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.